Gray Market Watchdog

The GLP-1 Gray Market, Explained: What Vendors Show You vs. What the Documentation Actually Says

Billions in pharmaceutical revenue have spawned a shadow market for GLP-1 and dual-agonist peptides. Here is what we found when we looked past the landing pages.

By Investigations Desk · Reviewed by M. Cho, PharmD · July 12, 2026 · 8 min read

What we found

The GLP-1 gray market refers to the online sale of research-grade peptides such as semaglutide, tirzepatide, and retatrutide analogs by vendors operating outside FDA oversight. These compounds are not approved for human use in their research-chemical form, and the branded pharmaceutical versions (Wegovy, Ozempic, Mounjaro, Zepbound) require a prescription. Credible vendors in this space provide third-party certificates of analysis from accredited labs; sellers who rely on marketing copy alone and cannot produce verifiable documentation are a documented consumer risk.

What the Gray Market Actually Is

The term 'gray market' describes commerce that is neither clearly legal nor clearly illegal under current enforcement priorities. For GLP-1 receptor agonists, the gray market sits at the intersection of three realities: surging consumer demand, ongoing pharmaceutical shortages, and a regulatory framework that has not kept pace with the peptide research-chemical trade. Vendors typically sell these compounds labeled 'for research use only,' a designation that is legally meaningful in narrow laboratory contexts but is widely understood to be a liability shield rather than a genuine use-case description.

The compounds most commonly sold in this space include semaglutide analogs, tirzepatide analogs, and retatrutide. To be precise about approvals: semaglutide is the active ingredient in FDA-approved Wegovy and Ozempic, both of which require a prescription. Tirzepatide is the active ingredient in FDA-approved Mounjaro and Zepbound, also prescription-only. Retatrutide has no approved pharmaceutical form as of mid-2025; it remains in clinical trials. Research-chemical versions of any of these compounds are not FDA-approved and are not equivalent to the branded drugs, regardless of how a vendor describes them.

The FDA has taken enforcement action against compounding pharmacies and online sellers in this space. In 2024, the agency issued warning letters to multiple parties selling compounded semaglutide products after the shortage designation for Wegovy was resolved. Those actions are public record on the FDA's website. What the agency has not done is systematically regulate the broader research-chemical peptide trade, which means consumers are largely on their own when evaluating vendor claims.

What Documentation a Credible Vendor Actually Provides

The single most important document in this market is a certificate of analysis, commonly called a CoA. A CoA from a credible vendor is issued by an independent, accredited third-party laboratory, not by the vendor's own in-house team. It should identify the testing lab by name, include a batch or lot number that matches the product being sold, report purity as a percentage with the analytical method used (typically HPLC or mass spectrometry), and carry a date. A CoA that lists the vendor's own name as the issuing lab is not independent verification.

Beyond purity, a complete CoA for a peptide should include testing for residual solvents, heavy metals, and microbial contamination. These are not optional extras. A peptide that tests at 99% purity on HPLC but has not been screened for endotoxins or microbial load carries risks that the purity number does not capture. We have reviewed vendor documentation across this market and found that a significant portion of sellers publish only a purity figure, sometimes without a lab name, sometimes without a batch number, and sometimes as a static image that cannot be cross-referenced with any external source.

Some vendors now publish QR codes or portal links that allow buyers to pull a CoA directly from the testing lab's own database. That is the current best practice. It is harder to fabricate than a PDF and creates a verifiable chain of custody. When a vendor cannot or will not provide this level of documentation, the claim that their product is research-grade is marketing, not evidence.

The Regulatory Backdrop: Where the Law Actually Stands

The FDA regulates drugs, not research chemicals per se, but the line between those categories is not as clean as gray-market vendors imply. Under the Federal Food, Drug, and Cosmetic Act, a substance intended for use in humans is a drug regardless of how it is labeled. The 'research use only' label does not exempt a product from drug regulations if the vendor's marketing, customer communications, or product descriptions suggest human use. The FDA has used this argument successfully in enforcement actions.

The DEA is a separate consideration for some peptides. Most GLP-1 analogs are not scheduled controlled substances, so DEA scheduling is not the primary legal risk here. The primary risk is FDA enforcement under the drug misbranding and adulteration provisions of the FD&C Act, plus potential action under the Controlled Substances Act if a product is found to contain an undisclosed scheduled compound, which has happened in the broader research-chemical market.

State law adds another layer. Several states have enacted their own regulations on the sale of research chemicals, and some state pharmacy boards have moved against online sellers operating within their jurisdictions. A vendor incorporated in one state and shipping to another is subject to the laws of both. This is not a theoretical risk; state-level enforcement actions against peptide sellers have been documented in California, Florida, and Texas in recent years.

Consumer Risks Beyond the Legal Question

Legal exposure is one risk. Product quality is a separate and arguably more immediate one. A 2023 analysis published in JAMA Internal Medicine examined compounded semaglutide products and found significant variability in labeled versus actual content. While that study focused on compounded pharmacy products rather than research-chemical vendors, it illustrates the quality-control problem that exists when manufacturing is not subject to FDA's current Good Manufacturing Practice regulations. Research-chemical vendors are not required to follow cGMP standards.

Contamination is a documented risk in this supply chain. Peptides synthesized outside cGMP facilities have tested positive for bacterial endotoxins, residual synthesis reagents, and in some cases entirely different compounds than what was labeled. The consequences of injecting a contaminated peptide range from injection-site reactions to systemic infection. These are not hypothetical outcomes; they have been reported in case literature and in FDA adverse event filings.

There is also the information problem. Consumers purchasing from gray-market vendors typically have no access to medical supervision, no baseline labs, and no follow-up care. The clinical trials that generated the evidence base for GLP-1 receptor agonists were conducted under controlled conditions with regular monitoring. That context does not transfer to unsupervised use of an unverified compound purchased online. Readers who are interested in GLP-1 therapies for legitimate medical purposes have access to physician-supervised options through licensed telehealth providers and compounding pharmacies operating under valid prescriptions.

What We Could Not Verify

In reviewing vendor claims across this market, we found several categories of assertions that we could not confirm. First, claims of 'pharmaceutical grade' purity. This phrase has no regulatory definition in the research-chemical context. Pharmaceutical grade is a standard applied to drugs manufactured under FDA oversight. A research-chemical vendor using this phrase is borrowing regulatory credibility they have not earned and cannot substantiate.

Second, claims about the identity of testing laboratories. Several vendors name labs in their marketing materials that do not appear in any accreditation database we could locate, including the databases maintained by A2LA and NELAP. We are not asserting those labs do not exist, but we could not confirm their accreditation status, and vendors did not respond to requests for clarification.

Third, claims about sourcing. Multiple vendors describe their peptides as 'USA-synthesized' or 'domestic.' We found no documentation to support or refute these claims in most cases. Synthesis location matters because it affects which regulatory standards, if any, apply to the manufacturing process. A vendor that cannot produce a chain-of-custody document linking their product to a specific synthesis facility is asking buyers to take their word for it. In this market, that is not a reasonable ask.

Want a legitimate, prescribed route?

This desk does not endorse vendors. If you are pursuing GLP-1 treatment, speak with a licensed clinician about FDA-approved options.

Check eligibility for physician-supervised GLP-1 programs

We may earn a commission if you buy through this link.

Frequently asked questions

Is it legal to buy GLP-1 peptides from a research vendor in the United States?

The legal status is genuinely ambiguous and depends on how the FDA characterizes the transaction. Research-chemical vendors sell these compounds under 'research use only' labels, but the FDA has the authority to treat a compound as a drug if marketing or context implies human use. The agency has issued warning letters and pursued enforcement actions in this space, particularly against compounded semaglutide sellers after the Wegovy shortage was resolved in 2024. Buyers face potential legal exposure, and the risk is not zero even if enforcement has been inconsistent.

How do I tell if a vendor's certificate of analysis is real?

A legitimate CoA names a specific third-party accredited laboratory, includes a batch or lot number that matches the product, states the analytical method used (HPLC, mass spectrometry, or both), and carries a date. The most verifiable CoAs link directly to the testing lab's own database via a QR code or portal. If the CoA lists the vendor as the issuing lab, if it has no batch number, or if it cannot be cross-referenced with an external source, it does not constitute independent verification. You can check whether a named lab holds accreditation through the A2LA public directory at a2la.org.

What is the difference between compounded semaglutide and research-chemical semaglutide?

Compounded semaglutide is produced by a licensed compounding pharmacy operating under a valid prescription and, when done lawfully, under FDA oversight frameworks that apply to compounders. Research-chemical semaglutide is sold by vendors outside the pharmaceutical supply chain, with no prescription requirement and no mandatory adherence to FDA's current Good Manufacturing Practice standards. The 2023 JAMA Internal Medicine analysis found quality variability in compounded products; research-chemical products face even fewer quality controls. Neither is the same as FDA-approved Wegovy or Ozempic, which are manufactured by Novo Nordisk under full cGMP oversight.

Sources

Woo et al., 2023, JAMA Internal Medicine – Compounded Semaglutide Quality Documents variability in compounded semaglutide product content
Jastreboff et al., 2022, NEJM – Retatrutide Phase 2 Trial Phase 2 human trial data for retatrutide, no approved form exists
Wilding et al., 2021, NEJM – Semaglutide STEP 1 Trial Pivotal RCT for Wegovy approval; prescription drug context

Best Reta Vendors